Pulse Biosciences Q3 net loss $10.6M; advances cardiac ablation devices toward 510(k) and first-in-human

PULSE BIOSCIENCES, INC.

GAAP net loss of $10.6M for Q3 2023 vs $18.0M in Q3 2022; non-GAAP net loss $8.5M vs $16.8M.
Cash and cash equivalents $50.4M as of Sept 30, 2023 vs $69.2M a year ago; Q3 cash burn $8.7M.
Plan to file 510(k) for cardiac ablation surgical clamp and initiate first-in-human catheter procedure between Dec 2023 and Q1 2024.
Appointed Dr. Niv Ad as Chief Science Officer, Cardiac Surgery to lead clinical strategy.
Completed treatment of 21 subjects in thyroid clinical feasibility study; started additional group Nov 7, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

PULSE BIOSCIENCES, INC. reported the third quarter ended September 30, 2023 results: net income ($10.6) million.

Period: the third quarter ended September 30, 2023
Net income: ($10.6) million
Result: reported results

Exact text from the filing

GAAP net loss for the three months ended September 30, 2023 was ($10.6) million compared to ($18.0) million for the three months ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

PULSE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-031425

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.